HIP
BLCM

Hatteras Investment Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Hatteras Investment Partners’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,041
Closed -$211K – 109
2015
Q4 		$211K Buy
+1,041
New +$186K 0.28% 93

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hatteras Investment Partners's BLCM Position: Q1 2016 in Review

Hatteras Investment Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2016, closing a stake of 1,041 shares — an estimated $211K sold.

Hatteras Investment Partners first reported a position in BLCM in Q4 2015 and held it in 1 quarter. The position peaked at $211K in Q4 2015. 78 funds tracked by Wall St. Rank hold BLCM as of Q1 2016.

  • Hatteras Investment Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Hatteras Investment Partners sold 1,041 Bellicum Pharmaceuticals, Inc. shares in Q1 2016, an estimated $211K.
  • Hatteras Investment Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's Bellicum Pharmaceuticals, Inc. position peaked at $211K in Q4 2015.
  • 78 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2016.

Based on Hatteras Investment Partners's 13F filing for Q1 2016, filed 16 May 2016.